These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27679712)

  • 1. FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde.
    Cianciolo G; Cozzolino M
    Clin Kidney J; 2016 Oct; 9(5):665-8. PubMed ID: 27679712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
    J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
    Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
    Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What would we like to know, and what do we not know about fibroblast growth factor 23?
    Cozzolino M; Galassi A; Apetrii M; Covic A
    J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease.
    Cozzolino M; Mazzaferro S
    Curr Vasc Pharmacol; 2010 May; 8(3):404-11. PubMed ID: 20180772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF23: its role in renal bone disease.
    Fukagawa M; Kazama JJ
    Pediatr Nephrol; 2006 Dec; 21(12):1802-6. PubMed ID: 16932898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
    Cancela AL; Oliveira RB; Graciolli FG; dos Reis LM; Barreto F; Barreto DV; Cuppari L; Jorgetti V; Carvalho AB; Canziani ME; Moysés RM
    Nephron Clin Pract; 2011; 117(1):c74-82. PubMed ID: 20689328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Kidney and bone update : the 5-year history and future of CKD-MBD. CKD-MBD and phosphotropic hormones].
    Fukumoto S
    Clin Calcium; 2012 Jul; 22(7):987-91. PubMed ID: 22750930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].
    Komaba H
    Clin Calcium; 2010 Jul; 20(7):1028-36. PubMed ID: 20585181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented Fibroblast Growth Factor-23 Secretion in Bone Locally Contributes to Impaired Bone Mineralization in Chronic Kidney Disease in Mice.
    Andrukhova O; Schüler C; Bergow C; Petric A; Erben RG
    Front Endocrinol (Lausanne); 2018; 9():311. PubMed ID: 29942284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
    Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial.
    Han N; Hong SH; Kim YS; Kim DK; Kim IW; Ji E; Oh JM
    Ther Clin Risk Manag; 2017; 13():999-1007. PubMed ID: 28860784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF23: a key player in mineral and bone disorder in CKD.
    Komaba H; Fukagawa M
    Nefrologia; 2009; 29(5):392-6. PubMed ID: 19820750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
    Moe SM; Radcliffe JS; White KE; Gattone VH; Seifert MF; Chen X; Aldridge B; Chen NX
    J Bone Miner Res; 2011 Nov; 26(11):2672-81. PubMed ID: 21826734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
    Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
    J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of associated secondary hyperparathyroidism to serum fibroblast growth factor-23 in end stage renal disease: a case-control study.
    Sliem H; Tawfik G; Moustafa F; Zaki H
    Indian J Endocrinol Metab; 2011 Apr; 15(2):105-9. PubMed ID: 21731867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.
    Stubbs J; Liu S; Quarles LD
    Semin Dial; 2007; 20(4):302-8. PubMed ID: 17635819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the role of fibroblast growth factor 23 in chronic kidney disease.
    Nakai K; Komaba H; Fukagawa M
    J Nephrol; 2010; 23(6):619-25. PubMed ID: 20658451
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.